Now, Eli Lilly says its experimental GLP-1 pill is a success after the first phase-three trial. The company said more than 3,000 adults on the experimental oral medication lowered their weight by an ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein ...

As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

A recent study suggests that Eli Lilly's new weight-loss medication helped individuals lose significant amounts of ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

For weight loss drug leaders, the last two weeks have been nothing short of disastrous for shares. Industry pioneer Novo ...

US investors weigh conflicting feelings about a dovish interest rate policy and the potential loss of independence at the Fed ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...